v3.26.3
Insider Trading Arrangements - USD ($)
$ in Thousands
3 Months Ended
Nov. 13, 2026
Sep. 30, 2026
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  

Item 5. Other Information.

On November 14, 2026, or the Appointment Date, Tobin Schilke was appointed to the Company’s Board of Directors. Mr. Schilke will serve as a director with a term of office expiring at the Company’s 2029 Annual Meeting of Stockholders. Mr. Schilke, age 52, served as Chief Financial Officer of Crinetics Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from February 2025 until its acquisition by Vertex Pharmaceuticals Incorporated in September 2026. Previously, Mr. Schilke served as Chief Financial Officer of Revance Therapeutics, Inc., a publicly traded biotechnology company, from November 2018 to February 2025. Mr. Schilke holds a B.S. in Chemical Engineering from Lafayette College, an M.S. in Chemical Engineering from the University of California, Berkeley, and an M.B.A. from Cornell University.

In accordance with the Company’s Non-Employee Director Compensation Policy, or the Director Compensation Policy, Mr. Schilke is eligible to participate in the Company’s standard compensation arrangements for non-employee directors which consists of cash and equity compensation for service on the Board. Pursuant to the Director Compensation Policy, Mr. Schilke is entitled to $40,000 in annual cash compensation for service on the Board with additional cash compensation payable for committee service. In addition, pursuant to the Director Compensation Policy, Mr. Schilke was granted an initial stock option award for 70,000 shares on the Appointment Date and is expected to be granted additional equity awards consistent with the terms of the Director Compensation Policy, including an annual option to purchase 35,000 shares, effective on the date of each annual meeting of stockholders.

There are no arrangements or understandings between Mr. Schilke and any other persons pursuant to which Mr. Schilke was appointed a director of the Company, and there are no family relationships between Mr. Schilke and any director or executive officer of the Company.

The Company has entered into its standard form of indemnification agreement with Mr. Schilke, a copy of which is filed as Exhibit 10.4 to the Company’s Registration Statement on Form S-1 (File No. 333-274777) on September 29, 2023. Other than the indemnification agreement, Mr. Schilke has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed.

Rule 10b5-1 Arrangement Adopted   false
Non-Rule 10b5-1 Arrangement Adopted   false
Rule 10b5-1 Arrangement Terminated   false
Non-Rule 10b5-1 Arrangement Terminated   false
Mr. Schilke [Member]    
Trading Arrangements, by Individual    
Name Mr. Schilke  
Title Board of Directors  
Expiration Date 2029  
Arrangement Duration 1145 days  
Aggregate Available 70,000  
Annual Cash Compensation $ 40,000  
Number of shares annual option to purchase 35,000